Cited by 909CAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

CAR T Cell Therapy for Solid Tumors

Open access

Newick, Kheng, O'Brien, Shaun, Moon, Edmund, Albelda, Steven M.·2017·Annual Review of Medicine

DOI 10.1146/annurev-med-062315-120245

Open this paper in CoChat — free account Open PDF

Abstract

The field of cancer immunotherapy has been re-energized by the application of chimeric antigen receptor (CAR) T cell therapy in cancers. These CAR T cells are engineered to express synthetic receptors that redirect polyclonal T cells to surface antigens for subsequent tumor elimination. Many CARs are designed with elements that augment T cell persistence and activity. To date, CAR T cells have demonstrated tremendous success in eradicating hematologic malignancies (e.g., CD19 CARs in leukemias). However, this success has yet to be extrapolated to solid tumors, and the reasons for this are being actively investigated. We characterize some of the challenges that CAR T cells have to surmount in the solid tumor microenvironment and new approaches that are being considered to overcome these hurdles.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1146/annurev-med-062315-120245

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
TGFβ in Cancer
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature reviews. Immunology · doi:10.1038/nri2785 · Cited by 2,524
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Louis, C. U., Savoldo, B., Dotti, G., Pulè, M. A., Yvon, E. S., Myers, G. D., Rössig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,174
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., der Meer, D. M. A. B.-V., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,101
Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Sukumar, M., Liu, J., Ji, Y., Subramanian, M., Crompton, J. G., Yu, Z., Roychoudhuri, R., Palmer, D. C., Muranski, P., Karoly, E. D., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69589 · Cited by 952
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. Μ., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 880
Self-citation
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. P., & Sadelain, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 860
Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways
Jacobs, S. R., Herman, C. E., MacIver, N. J., Wofford, J. A., Wieman, H. L., Hammen, J. J., & Rathmell, J. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4476 · Cited by 853
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 844
Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell.
Goodwin, J. S., Bankhurst, A. D., & Messner, R. P. (1977) · The Journal of Experimental Medicine · doi:10.1084/jem.146.6.1719 · Cited by 796
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
John, L. B., Devaud, C., Duong, C. P. M., Yong, C. S. M., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 711
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Pegram, H. J., Lee, J., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 686
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653
Self-citation
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Adusumilli, P. S., Cherkassky, L., Villena‐Vargas, J., Colovos, C., Servais, E. L., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 582
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J. D., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. Μ. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 545
Self-citation
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
Craddock, J. A., Lu, A., Bear, A. S., Pulè, M. A., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 514
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. S. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 491
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Wilkie, S., van Schalkwyk, M. C., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. F. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 491
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M. G., Byrd, T. T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 469
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain
Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 469
Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A., Dentchev, T., Thekkat, P. U., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 459
Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Zhang, L., Morgan, R. A., Beane, J. D., Zheng, Z., Dudley, M. E., Kassim, S. H., Nahvi, A. V., Ngo, L. T., Sherry, R. M., Phan, G. Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2085 · Cited by 445
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
Moon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2627 · Cited by 410
Self-citation
Of CAR s and TRUCK s: chimeric antigen receptor ( CAR ) T cells engineered with an inducible cytokine to modulate the tumor stroma
Chmielewski, M. M., Hombach, A. A., & Abken, H. (2013) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 365
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
Song, D.-G., Ye, Q., Poussin, M., Pritchard, G. H., Figini, M., & Powell, D. J. (2011) · Blood · doi:10.1182/blood-2011-03-344275 · Cited by 362
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 359
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor‐Papadimitriou, J., Burchell, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4901 · Cited by 345
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D.-G., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 339
Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor–Modified T Cells in Solid Tumors
Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier‐Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 337
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Ninomiya, S., Narala, N., Huye, L. E., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 324
TGF-β: Guardian of T Cell Function
Oh, S. A., & Li, M. O. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301843 · Cited by 322
Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity
Bollard, C. M., Rössig, C., Calonge, M. J., Huls, M. H., Wagner, H.-J., Massagué, J., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2002) · Blood · doi:10.1182/blood.v99.9.3179 · Cited by 316
Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 310
EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
Sampson, J. H., Choi, B. D., Sanchez-Perez, L. A., Suryadevara, C. M., Snyder, D. J., Flores, C., Schmittling, R. J., Nair, S. K., Reap, E. A., Norberg, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0709 · Cited by 299
Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer
Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5023-8 · Cited by 297
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
Zhou, Q., Munger, M. E., Highfill, S. L., Tolar, J., Weigel, B. J., Riddle, M. J., Sharpe, A. H., Vallera, D. A., Azuma, M., Levine, B. L., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275446 · Cited by 294
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Pastan, I. H., & Hassan, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0337 · Cited by 252
Chimeric antigen receptor T cell therapy: 25years in the making
Gill, S. I., Maus, M. V., & Porter, D. L. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.10.003 · Cited by 245
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T
Burga, R. A., Thorn, M., Point, G. R., Guha, P., Nguyen, C. T., Licata, L. A., DeMatteo, R. P., Ayala, A., Espat, N. J., Junghans, R. P., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1692-6 · Cited by 232
IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell–mediated rejection of systemic lymphoma in immunodeficient mice
Markley, J. C., & Sadelain, M. (2010) · Blood · doi:10.1182/blood-2009-09-241398 · Cited by 228
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity
Chowdhury, P. S., Viner, J. L., Beers, R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.669 · Cited by 223
Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., Purdon, T. J., Pegram, H. J., & Brentjens, R. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.4 · Cited by 223
Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity
Liu, Y., Wang, L., Predina, J. D., Han, R., Beier, U. H., Wang, L. S., Kapoor, V., Bhatti, T. R., Akimova, T., Singhal, S. K., et al. (2013) · Nature Medicine · doi:10.1038/nm.3286 · Cited by 207
Self-citation
Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
Yao, X., Ahmadzadeh, M., Lu, Y., Liewehr, D. J., Dudley, M. E., Liu, F., Schrump, D. S., Steinberg, S. M., Rosenberg, S. A., & Robbins, P. F. (2012) · Blood · doi:10.1182/blood-2011-10-386482 · Cited by 207
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Newick, K., O’Brien, S., Sun, J., Kapoor, V., Maceyko, S., Lo, A., Puré, E., Moon, E. K., & Albelda, S. Μ. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0263 · Cited by 202
Self-citation
Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
Lanitis, E., Poussin, M., Hagemann, I. S., Coukos, G., Sandaltzopoulos, R., Scholler, N., & Powell, D. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.256 · Cited by 189
Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen
Chekmasova, A. A., Rao, T. D., Nikhamin, Y., Park, K. J., Levine, D. A., Spriggs, D. R., & Brentjens, R. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0192 · Cited by 172
Bcl-2 overexpression enhances tumor-specific T-cell survival.
Charo, J., Finkelstein, S., Grewal, N. S., Restifo, N., Robbins, P., & Rosenberg, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2006 · Cited by 142
CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation
Kofler, D. M., Chmielewski, M. M., Rappl, G., Hombach, A., Riët, T., Schmidt, A., Hombach, A. A., Wendtner, C., & Abken, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.9 · Cited by 140
Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Perna, S. K., Pagliara, D., Mahendravada, A., Liu, H., Brenner, M. K., Savoldo, B., & Dotti, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1016 · Cited by 131
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
Riese, M. J., Wang, L. S., Moon, E. K., Joshi, R. P., Ranganathan, A., June, C. H., Koretzky, G. A., & Albelda, S. Μ. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3874 · Cited by 128
Self-citation
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Moon, E. K., Ranganathan, R., Eruslanov, E. B., Kim, S., Newick, K., O’Brien, S., Lo, A., Liu, X., Zhao, Y., & Albelda, S. Μ. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1070 · Cited by 126
Self-citation
Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy
Kobold, S., Grassmann, S. A., Chaloupka, M., Lampert, C., Wenk, S., Kraus, F. B. T., Rapp, M., Duewell, P., Zeng, Y., Schmollinger, J. C., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv146 · Cited by 121
Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity
Mussai, F., Egan, S. A., Hunter, S., Webber, H. T., Fisher, J. P. H., Wheat, R. L., McConville, C. M., Sbirkov, Y., Wheeler, K., Bendle, G. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3443 · Cited by 115
Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF
Spear, P., Barber, A., Rynda‐Apple, A., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103019 · Cited by 114
Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Wang, E., Wang, L.-C., Tsai, C., Bhoj, V. G., Gershenson, Z., Moon, E. K., Newick, K., Sun, J., Lo, A., Baradet, T. C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0054 · Cited by 113
Self-citation
Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice
Chinnasamy, D., Tran, E., Yu, Z., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3913 · Cited by 108
Starved and Asphyxiated: How Can CD8+ T Cells within a Tumor Microenvironment Prevent Tumor Progression
Zhang, Y., & Ertl, H. C. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00032 · Cited by 102
Engager T Cells: A New Class of Antigen-specific T Cells That Redirect Bystander T Cells
Iwahori, K., Kakarla, S., Velasquez, M. P., Feng, Y., Yi, Z., Gerken, C. P., Song, X., & Gottschalk, S. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.156 · Cited by 100
The Evolution of T-cell Therapies for Solid Malignancies
Fousek, K., & Ahmed, N. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2675 · Cited by 90
Transforming Growth Factor-β Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers
Wallace, A. F., Kapoor, V., Sun, J., Mrass, P., Weninger, W., Heitjan, D. F., June, C. H., Kaiser, L. R., Ling, L. E., & Albelda, S. Μ. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0356 · Cited by 85
Self-citation
T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice
VanSeggelen, H., Hammill, J. A., Dvorkin‐Gheva, A., Tantalo, D. G. M., Kwiecień, J. M., Denisova, G. F., Rabinovich, B. A., Wan, Y., & Bramson, J. L. (2015) · Molecular Therapy · doi:10.1038/mt.2015.119 · Cited by 76
A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes
Willemsen, R., Debets, R., Hart, E., Hoogenboom, H. R., Bolhuis, R., & Chames, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301570 · Cited by 76
Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP–PKA signaling and immunosuppression
Su, Y., Huang, X., Raskovalova, T., Zacharia, L. C., Lokshin, A. E., Jackson, E. K., & Gorelik, E. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0494-5 · Cited by 68
Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA × anti-CD3 diabodies from lentivirally transduced human lymphocytes
Compte, M., Blanco, B., Serrano, F., et al. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701021 · Cited by 64
Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment
Howie, D., Waldmann, H., & Cobbold, S. P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00409 · Cited by 62
CTLA-4 Blockade Plus Adoptive T-Cell Transfer Promotes Optimal Melanoma Immunity in Mice
Mahvi, D. A., Meyers, J. V., Tatar, A. J., Contreras, A., Suresh, M., LEVERSON, G. E., Sen, S., & Cho, C. S. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000064 · Cited by 42
Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation
Veliça, P., Zech, M., Henson, S. M., Holler, A., Manzo, T., Pike, R., Sousa, P. S. E., Zhang, L., Schiedlmeier, B., Pulè, M. A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3283 · Cited by 25
Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road
Wang, L.-C., Riese, M. J., Moon, E. K., et al. (2013) · OncoImmunology · doi:10.4161/onci.26492 · Cited by 6
Self-citation

Sorted by citations

Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity
Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Targeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933

See all 909

Authors: Newick, K., O'Brien, S., Moon, E., & Albelda, S. M.
Affiliations: University of Pennsylvania (US)
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104;
ORCID: Moon, Edmund
Venue: Annual Review of Medicine
Publisher: Annual Reviews
Published: 2017-01-14
Volume: 68
Issue: 1
Pages: 139-152
ISSN: 0066-4219 (ISSN-L)
1545-326X
DOI: 10.1146/annurev-med-062315-120245
OpenAlex: W2475107749
Cited by: 909
References: 77
Citations by year: 2026: 89 · 2025: 96 · 2024: 97 · 2023: 98 · 2022: 124 · 2021: 128 · 2020: 123 · 2019: 73 · 2018: 48 · 2017: 32
FWCI: 5.13
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Annual Review of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (K08CA163941)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: CAR T-cell therapy, solid tumors, chimeric antigen receptor, cancer immunotherapy, tumor microenvironment, T cell persistence, hematologic malignancies, CD19, T cell redirection, tumor antigens
MeSH terms: Antigens, Neoplasm, Humans, Immune Tolerance, Immunity, Cellular, Neoplasms, Receptors, Antigen, T-Cell, T-Lymphocytes, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CAR T Cell Therapy for Solid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks